DiaMedica Therapeutics (DMAC) Company Overview

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - Chief Financial Officer & Company Secretary Lorianne Masuoka - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2024 Conference Call.

IAG, DMAC and HIVE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 14, 2024.

An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected to be worth $14 billion by 2032. Proof-of-concept data from a phase 2 study, using DM199 for the treatment of women with pregnancy complications, is expected 1st half of 2025.

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement agent was not used in connection with this private placement. Pursuant to the terms of t.

DiaMedica (DMAC) shares increase by 10% after the company administers the initial dose to the first patient in the restart of its crucial trial assessing the primary candidate, DM199, for the treatment of acute ischemic stroke.

DiaMedica Therapeutics (DMAC) is currently in oversold territory, indicating that the intense selling pressure may have subsided. Coupled with widespread consensus among Wall Street analysts in increasing earnings projections, this could result in a potential turnaround for the stock.

DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer. Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call.

Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.